Top
image credit: Adobe Stock

Merck makes circular RNA play with $3.5bn Orna alliance

August 16, 2022

Category:

It has also invested another $100 million in the three-year-old Cambridge, Massachusetts-based biotech, by participating in a $221 million Series B round.

One of the unexpected consequences of the COVID-19 vaccine race was that some top-tier vaccine companies like Merck, GSK and Sanofi ended up trailing the field, as their efforts to bring shots based on conventional technologies to patients were outstripped and outclassed by mRNA competitors from Pfizer/BioNTech and Moderna.

Some have sought to rectify that by buying into or doubling down on mRNA technologies, both for COVID-19 as well as for other diseases.

Read More on Pharmaphorum